Topic Hub
4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 4 of 4 clinical reviews.
Health-economic analysis of flibanserin (Addyi) from the BEGONIA trial: cost per QALY estimates, list-price vs net-price realities, payer coverage gaps, and individual value calculations for women with HSDD.
Read clinical reviewDeep dive into the BEGONIA trial's open-label extension, long-term durability of flibanserin (Addyi) for HSDD, safety signals over 52 weeks, and what post-trial data revealed about sustained efficacy.
Read clinical reviewA detailed analysis of the BEGONIA trial's enrollment biases, follow-up gaps, statistical caveats, and conflict-of-interest issues that shaped the FDA approval of flibanserin (Addyi) for HSDD.
Read clinical reviewA deep-dive into the BEGONIA trial's real-world clinical implications for flibanserin (Addyi) prescribing in HSDD, including guideline updates, prescribing shifts, and patient selection beyond the trial population.
Read clinical review